A monoclonal antibody (mAb, more rarely called moAb) is an antibody produced from a cell lineage made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell.
Monoclonal antibodies can have monovalent affinity, binding only to the same epitope (the part of an antigen that is recognized by the antibody). In contrast, polyclonal antibodies bind to multiple epitopes and are usually made by several different antibody-secreting plasma cell lineages. Bispecific monoclonal antibodies can also be engineered, by increasing the therapeutic targets of one monoclonal antibody to two epitopes.
It is possible to produce monoclonal antibodies that specifically bind to almost any suitable substance; they can then serve to detect or purify it. This capability has become an investigative tool in biochemistry, molecular biology, and medicine. Monoclonal antibodies are used in the diagnosis of illnesses such as cancer and infections[3] and are used therapeutically in the treatment of e.g. cancer and inflammatory diseases.
History
In the early 1900s, immunologistPaul Ehrlich proposed the idea of a Zauberkugel – "magic bullet", conceived of as a compound which selectively targeted a disease-causing organism, and could deliver a toxin for that organism. This underpinned the concept of monoclonal antibodies and monoclonal drug conjugates. Ehrlich and Élie Metchnikoff received the 1908 Nobel Prize for Physiology or Medicine for providing the theoretical basis for immunology.
By the 1970s, lymphocytes producing a single antibody were known, in the form of multiple myeloma – a cancer affecting B-cells. These abnormal antibodies or paraproteins were used to study the structure of antibodies, but it was not yet possible to produce identical antibodies specific to a given antigen.[4]: 324 In 1973, Jerrold Schwaber described the production of monoclonal antibodies using human–mouse hybrid cells.[5] This work remains widely cited among those using human-derived hybridomas.[6] In 1975, Georges Köhler and César Milstein succeeded in making fusions of myeloma cell lines with B cells to create hybridomas that could produce antibodies, specific to known antigens and that were immortalized.[7] They and Niels Kaj Jerne shared the Nobel Prize in Physiology or Medicine in 1984 for the discovery.[7]
In 1988, Gregory Winter and his team pioneered the techniques to humanize monoclonal antibodies,[8] eliminating the reactions that many monoclonal antibodies caused in some patients. By the 1990s research was making progress in using monoclonal antibodies therapeutically, and in 2018, James P. Allison and Tasuku Honjo received the Nobel Prize in Physiology or Medicine for their discovery of cancer therapy by inhibition of negative immune regulation, using monoclonal antibodies that prevent inhibitory linkages.[9]
The translational work needed to implement these ideas is credited to Lee Nadler. As explained in an NIH article, "He was the first to discover monoclonal antibodies directed against human B-cell–specific antigens and, in fact, all the known human B-cell–specific antigens were discovered in his laboratory. He is a true translational investigator, since he used these monoclonal antibodies to classify human B-cell leukemia and lymphomas as well as to create therapeutic agents for patients. . . More importantly, he was the first in the world to administer a monoclonal antibody to a human (a patient with B-cell lymphoma)."[10]
Much of the work behind production of monoclonal antibodies is rooted in the production of hybridomas, which involves identifying antigen-specific plasma/plasmablast cells that produce antibodies specific to an antigen of interest and fusing these cells with myeloma cells.[7] Rabbit B-cells can be used to form a rabbit hybridoma.[11][12]Polyethylene glycol is used to fuse adjacent plasma membranes,[13] but the success rate is low, so a selective medium in which only fused cells can grow is used. This is possible because myeloma cells have lost the ability to synthesize hypoxanthine-guanine-phosphoribosyl transferase (HGPRT), an enzyme necessary for the salvage synthesis of nucleic acids. The absence of HGPRT is not a problem for these cells unless the de novo purine synthesis pathway is also disrupted. Exposing cells to aminopterin (a folic acid analogue which inhibits dihydrofolate reductase) makes them unable to use the de novo pathway and become fully auxotrophic for nucleic acids, thus requiring supplementation to survive.
The selective culture medium is called HAT medium because it contains hypoxanthine, aminopterin and thymidine. This medium is selective for fused (hybridoma) cells. Unfused myeloma cells cannot grow because they lack HGPRT and thus cannot replicate their DNA. Unfused spleen cells cannot grow indefinitely because of their limited life span. Only fused hybrid cells referred to as hybridomas, are able to grow indefinitely in the medium because the spleen cell partner supplies HGPRT and the myeloma partner has traits that make it immortal (similar to a cancer cell).
This mixture of cells is then diluted and clones are grown from single parent cells on microtitre wells. The antibodies secreted by the different clones are then assayed for their ability to bind to the antigen (with a test such as ELISA or antigen microarray assay) or immuno-dot blot. The most productive and stable clone is then selected for future use.
The hybridomas can be grown indefinitely in a suitable cell culture medium. They can also be injected into mice (in the peritoneal cavity, surrounding the gut). There, they produce tumors secreting an antibody-rich fluid called ascites fluid.
The medium must be enriched during in vitro selection to further favour hybridoma growth. This can be achieved by the use of a layer of feeder fibrocyte cells or supplement medium such as briclone. Culture-media conditioned by macrophages can be used. Production in cell culture is usually preferred as the ascites technique is painful to the animal. Where alternate techniques exist, ascites is considered unethical.[14]
Novel mAb development technology
Several monoclonal antibody technologies have been developed recently,[15] such as phage display,[16] single B cell culture,[17] single cell amplification from various B cell populations[18][19][20][21][22] and single plasma cell interrogation technologies. Different from traditional hybridoma technology, the newer technologies use molecular biology techniques to amplify the heavy and light chains of the antibody genes by PCR and produce in either bacterial or mammalian systems with recombinant technology. One of the advantages of the new technologies is applicable to multiple animals, such as rabbit, llama, chicken and other common experimental animals in the laboratory.
Purification
After obtaining either a media sample of cultured hybridomas or a sample of ascites fluid, the desired antibodies must be extracted. Cell culture sample contaminants consist primarily of media components such as growth factors, hormones and transferrins. In contrast, the in vivo sample is likely to have host antibodies, proteases, nucleases, nucleic acids and viruses. In both cases, other secretions by the hybridomas such as cytokines may be present. There may also be bacterial contamination and, as a result, endotoxins that are secreted by the bacteria. Depending on the complexity of the media required in cell culture and thus the contaminants, one or the other method (in vivo or in vitro) may be preferable.
The sample is first conditioned, or prepared for purification. Cells, cell debris, lipids, and clotted material are first removed, typically by centrifugation followed by filtration with a 0.45 μm filter. These large particles can cause a phenomenon called membrane fouling in later purification steps. In addition, the concentration of product in the sample may not be sufficient, especially in cases where the desired antibody is produced by a low-secreting cell line. The sample is therefore concentrated by ultrafiltration or dialysis.
Most of the charged impurities are usually anions such as nucleic acids and endotoxins. These can be separated by ion exchange chromatography.[23] Either cation exchange chromatography is used at a low enough pH that the desired antibody binds to the column while anions flow through, or anion exchange chromatography is used at a high enough pH that the desired antibody flows through the column while anions bind to it. Various proteins can also be separated along with the anions based on their isoelectric point (pI). In proteins, the isoelectric point (pI) is defined as the pH at which a protein has no net charge. When the pH > pI, a protein has a net negative charge, and when the pH < pI, a protein has a net positive charge. For example, albumin has a pI of 4.8, which is significantly lower than that of most monoclonal antibodies, which have a pI of 6.1. Thus, at a pH between 4.8 and 6.1, the average charge of albumin molecules is likely to be more negative, while mAbs molecules are positively charged and hence it is possible to separate them. Transferrin, on the other hand, has a pI of 5.9, so it cannot be easily separated by this method. A difference in pI of at least 1 is necessary for a good separation.
Transferrin can instead be removed by size exclusion chromatography. This method is one of the more reliable chromatography techniques. Since we are dealing with proteins, properties such as charge and affinity are not consistent and vary with pH as molecules are protonated and deprotonated, while size stays relatively constant. Nonetheless, it has drawbacks such as low resolution, low capacity and low elution times.
A much quicker, single-step method of separation is protein A/Gaffinity chromatography. The antibody selectively binds to protein A/G, so a high level of purity (generally >80%) is obtained. The generally harsh conditions of this method may damage easily damaged antibodies. A low pH can break the bonds to remove the antibody from the column. In addition to possibly affecting the product, low pH can cause protein A/G itself to leak off the column and appear in the eluted sample. Gentle elution buffer systems that employ high salt concentrations are available to avoid exposing sensitive antibodies to low pH. Cost is also an important consideration with this method because immobilized protein A/G is a more expensive resin.
To achieve maximum purity in a single step, affinity purification can be performed, using the antigen to provide specificity for the antibody. In this method, the antigen used to generate the antibody is covalently attached to an agarose support. If the antigen is a peptide, it is commonly synthesized with a terminal cysteine, which allows selective attachment to a carrier protein, such as KLH during development and to support purification. The antibody-containing medium is then incubated with the immobilized antigen, either in batch or as the antibody is passed through a column, where it selectively binds and can be retained while impurities are washed away. An elution with a low pH buffer or a more gentle, high salt elution buffer is then used to recover purified antibody from the support.
Antibody heterogeneity
Product heterogeneity is common in monoclonal antibodies and other recombinant biological products and is typically introduced either upstream during expression or downstream during manufacturing.[citation needed]
These variants are typically aggregates, deamidation products, glycosylation variants, oxidized amino acid side chains, as well as amino and carboxyl terminal amino acid additions.[24] These seemingly minute structural changes can affect preclinical stability and process optimization as well as therapeutic product potency, bioavailability and immunogenicity. The generally accepted purification method of process streams for monoclonal antibodies includes capture of the product target with protein A, elution, acidification to inactivate potential mammalian viruses, followed by ion chromatography, first with anion beads and then with cation beads.[citation needed]
Displacement chromatography has been used to identify and characterize these often unseen variants in quantities that are suitable for subsequent preclinical evaluation regimens such as animal pharmacokinetic studies.[25][26] Knowledge gained during the preclinical development phase is critical for enhanced product quality understanding and provides a basis for risk management and increased regulatory flexibility. The recent Food and Drug Administration's Quality by Design initiative attempts to provide guidance on development and to facilitate design of products and processes that maximizes efficacy and safety profile while enhancing product manufacturability.[27]
Recombinant
The production of recombinant monoclonal antibodies involves repertoire cloning, CRISPR/Cas9, or phage display/yeast display technologies.[28] Recombinant antibody engineering involves antibody production by the use of viruses or yeast, rather than mice. These techniques rely on rapid cloning of immunoglobulin gene segments to create libraries of antibodies with slightly different amino acid sequences from which antibodies with desired specificities can be selected.[29] The phage antibody libraries are a variant of phage antigen libraries.[30] These techniques can be used to enhance the specificity with which antibodies recognize antigens, their stability in various environmental conditions, their therapeutic efficacy and their detectability in diagnostic applications.[31] Fermentation chambers have been used for large scale antibody production.
While mouse and human antibodies are structurally similar, the differences between them were sufficient to invoke an immune response when murine monoclonal antibodies were injected into humans, resulting in their rapid removal from the blood, as well as systemic inflammatory effects and the production of human anti-mouse antibodies (HAMA).
Recombinant DNA has been explored since the late 1980s to increase residence times. In one approach called "CDR grafting",[32] mouse DNA encoding the binding portion of a monoclonal antibody was merged with human antibody-producing DNA in living cells. The expression of this "chimeric" or "humanised" DNA through cell culture yielded part-mouse, part-human antibodies.[33][34]
Human antibodies
Ever since the discovery that monoclonal antibodies could be generated, scientists have targeted the creation of fully human products to reduce the side effects of humanised or chimeric antibodies. Several successful approaches have been proposed: transgenic mice,[35]phage display[16] and single B cell cloning.[15]
Cost
Monoclonal antibodies are more expensive to manufacture than small molecules due to the complex processes involved and the general size of the molecules, all in addition to the enormous research and development costs involved in bringing a new chemical entity to patients. They are priced to enable manufacturers to recoup the typically large investment costs, and where there are no price controls, such as the United States, prices can be higher if they provide great value. Seven University of Pittsburgh researchers concluded, "The annual price of mAb therapies is about $100,000 higher in oncology and hematology than in other disease states", comparing them on a per patient basis, to those for cardiovascular or metabolic disorders, immunology, infectious diseases, allergy, and ophthalmology.[36]
Applications
Diagnostic tests
Once monoclonal antibodies for a given substance have been produced, they can be used to detect the presence of this substance. Proteins can be detected using the Western blot and immuno dot blot tests. In immunohistochemistry, monoclonal antibodies can be used to detect antigens in fixed tissue sections, and similarly, immunofluorescence can be used to detect a substance in either frozen tissue section or live cells.
Analytic and chemical uses
Antibodies can also be used to purify their target compounds from mixtures, using the method of immunoprecipitation.
Therapeutic monoclonal antibodies act through multiple mechanisms, such as blocking of targeted molecule functions, inducing apoptosis in cells which express the target, or by modulating signalling pathways.[37][38][39]
Cancer treatment
One possible treatment for cancer involves monoclonal antibodies that bind only to cancer-cell-specific antigens and induce an immune response against the target cancer cell. Such mAbs can be modified for delivery of a toxin, radioisotope, cytokine or other active conjugate or to design bispecific antibodies that can bind with their Fab regions both to target antigen and to a conjugate or effector cell. Every intact antibody can bind to cell receptors or other proteins with its Fc region.
Monoclonal antibodies for research applications can be found directly from antibody suppliers, or through use of a specialist search engine like CiteAb. Below are examples of clinically important monoclonal antibodies.
As of December 2021, in vitro neutralization tests indicate monoclonal antibody therapies (with the exception of sotrovimab and tixagevimab/cilgavimab) were not likely to be active against the Omicron variant.[48]
Over 2021–22, two Cochrane reviews found insufficient evidence for using neutralizing monoclonal antibodies to treat COVID-19 infections.[49][50] The reviews applied only to people who were unvaccinated against COVID‐19, and only to the COVID-19 variants existing during the studies, not to newer variants, such as Omicron.[50]
In March 2024, pemivibart, a monoclonal antibody drug, received an emergency use authorization from the US FDA for use as pre-exposure prophylaxis to protect certain moderately to severely immunocompromised individuals against COVID-19.[51][52]
Side effects
Several monoclonal antibodies, such as bevacizumab and cetuximab, can cause different kinds of side effects.[53] These side effects can be categorized into common and serious side effects.[54]
^Schwaber J, Cohen EP (August 1973). "Human x mouse somatic cell hybrid clone secreting immunoglobulins of both parental types". Nature. 244 (5416): 444–447. doi:10.1038/244444a0. PMID4200460. S2CID4171375.
^Cambrosio A, Keating P (1992). "Between fact and technique: the beginnings of hybridoma technology". Journal of the History of Biology. 25 (2): 175–230. doi:10.1007/BF00162840. PMID11623041. S2CID45615711.
^National Research Council (US) Committee on Methods of Producing Monoclonal Antibodies. "Recommendation 1: Executive Summary: Monoclonal Antibody Production". Washington (DC): National Academies Press (US); 1999. ISBN978-0309075114
^Vlasak J, Ionescu R (December 2008). "Heterogeneity of monoclonal antibodies revealed by charge-sensitive methods". Current Pharmaceutical Biotechnology. 9 (6): 468–481. doi:10.2174/138920108786786402. PMID19075686.
^Beck A, Wurch T, Bailly C, Corvaia N (May 2010). "Strategies and challenges for the next generation of therapeutic antibodies". Nature Reviews. Immunology. 10 (5): 345–352. doi:10.1038/nri2747. PMID20414207. S2CID29689097.
^Zhang T, Bourret J, Cano T (August 2011). "Isolation and characterization of therapeutic antibody charge variants using cation exchange displacement chromatography". Journal of Chromatography A. 1218 (31): 5079–5086. doi:10.1016/j.chroma.2011.05.061. PMID21700290.
^"Dr. George Pieczenik". LMB Alumni. MRC Laboratory of Molecular Biology (LMB). 17 September 2009. Archived from the original on 23 December 2012. Retrieved 17 November 2012.
^Schmitz U, Versmold A, Kaufmann P, Frank HG (2000). "Phage display: a molecular tool for the generation of antibodies – a review". Placenta. 21 (Suppl A): S106–S112. doi:10.1053/plac.1999.0511. PMID10831134.
^Chadd HE, Chamow SM (April 2001). "Therapeutic antibody expression technology". Current Opinion in Biotechnology. 12 (2): 188–194. doi:10.1016/S0958-1669(00)00198-1. PMID11287236.
^Lonberg N, Huszar D (1995). "Human antibodies from transgenic mice". International Reviews of Immunology. 13 (1): 65–93. doi:10.3109/08830189509061738. PMID7494109.
^Hernandez I, Bott SW, Patel AS, Wolf CG, Hospodar AR, Sampathkumar S, et al. (February 2018). "Pricing of monoclonal antibody therapies: higher if used for cancer?". The American Journal of Managed Care. 24 (2): 109–112. PMID29461857.
^Modified from Carter P (November 2001). "Improving the efficacy of antibody-based cancer therapies". Nature Reviews. Cancer. 1 (2): 118–129. doi:10.1038/35101072. PMID11905803. S2CID10169378.
^ abcdefghijRang HP (2003). Pharmacology. Edinburgh: Churchill Livingstone. pp. 241, for the examples infliximab, basiliximab, abciximab, daclizumab, palivusamab, gemtuzumab, alemtuzumab and rituximab, and mechanism and mode. ISBN978-0443071454.
^Cavazzoni P (3 April 2024). "EUA 122 Invivyd Pemgarda LOA". U.S. Food and Drug Administration. Archived from the original on 8 April 2024. Retrieved 8 April 2024.
Artikel ini memiliki beberapa masalah. Tolong bantu memperbaikinya atau diskusikan masalah-masalah ini di halaman pembicaraannya. (Pelajari bagaimana dan kapan saat yang tepat untuk menghapus templat pesan ini) Artikel ini terlalu bergantung pada referensi dari sumber primer. Mohon perbaiki artikel ini dengan menambahkan sumber sekunder atau tersier. (Pelajari cara dan kapan saatnya untuk menghapus pesan templat ini) Artikel ini kemungkinan menggunakan bahan sumber yang tidak independen dari sub…
Artikel ini sebatang kara, artinya tidak ada artikel lain yang memiliki pranala balik ke halaman ini.Bantulah menambah pranala ke artikel ini dari artikel yang berhubungan atau coba peralatan pencari pranala.Tag ini diberikan pada Desember 2022. Artikel ini sebatang kara, artinya tidak ada artikel lain yang memiliki pranala balik ke halaman ini.Bantulah menambah pranala ke artikel ini dari artikel yang berhubungan atau coba peralatan pencari pranala.Tag ini diberikan pada Oktober 2022. Nyalawena…
Tujuh FuqahaMadinah Said bin al-Musayyib Al-Qasim bin Muhammad Sulaiman bin Yasar Urwah bin az-Zubair Kharijah bin Zaid bin Tsabit Ubaidillah bin Abdullah bin Utbah Abubakar bin Abdurrahman lbs Untuk artikel mengenai anak Nabi Muhammad, lihat Qasim bin Muhammad. Al-Qasim bin MuhammadNama dalam bahasa asli(ar) القاسم بن محمد بن أبي بكر BiografiKelahiran660 (Kalender Masehi Gregorius) Kematian730 (Kalender Masehi Gregorius) (69/70 tahun)Data pribadiAgamaIslam KegiatanSpesialisa…
American physician (born 1949) Peter AgreBorn (1949-01-30) January 30, 1949 (age 75)Northfield, Minnesota, U.S.Alma materAugsburg College (BA)Johns Hopkins University (MD)Known forAquaporinsAwardsNobel Prize in Chemistry (2003) Bloomberg Distinguished Professorships (2014)Scientific careerFieldsMedicineChemistryBiochemistryInstitutionsJohns Hopkins Malaria Research Institute Duke University Case Western Reserve Peter Agre (/ˈɑːɡriː/; born January 30, 1949) is an American phys…
Květa PeschkeNama lengkapKvětoslava PeschkeKebangsaan CekoTempat tinggalSarasota, Florida, Amerika SerikatLahir9 Juli 1975 (umur 48)Bílovec, CekoslowakiaTinggi165 m (541 ft 4 in)[1]Memulai pro27 April 1993Rekor (M–K)322–213Rekor (M–K)662–386 Květoslava Peschke (née Hrdličková; lahir 9 Juli 1975) adalah seorang pemain tenis profesional asal Ceko yang biasanya bermain dalam kategori ganda.[2] Peschke menikahi pelatihnya, Torsten Peschke, pada…
Berberia Klasifikasi ilmiah Kerajaan: Animalia Filum: Arthropoda Kelas: Insecta Ordo: Lepidoptera Famili: Nymphalidae Subfamili: Satyrinae Genus: Berberiade Lesse, 1951 Species Lihat teks. Berberia adalah genus kupu-kupu dari subfamili Satyrinae dalam famili Nymphalidae. Spesies dalam genus Berberia tersebar di Afrika Utara. Spesies Berberia abdelkader (Pierret, 1837) Berberia lambessanus (Staudinger, 1901) Pranala luar Satyrinae of the Western Palearctic Pengidentifikasi takson Wikidata: Q17580…
Halaman ini berisi artikel tentang aktris kelahiran 1923. Untuk aktris dengan nama serupa lahir tahun 1949, lihat Gloria Hendry. Gloria HenryGloria Henry, circa 1947LahirGloria Eileen McEniry(1923-04-02)2 April 1923New Orleans, Louisiana, A.S.Meninggal3 April 2021(2021-04-03) (umur 98)Los Angeles, California, A.S.PekerjaanAktrisTahun aktif1947–2005, 2012Suami/istriRobert D. Lamb (m. 1943; c. 1948)Craig Ellwood …
Town in Western AustraliaPeppermint Grove BeachWestern AustraliaLooking east from the lookout in Peppermint Grove BeachPeppermint Grove BeachCoordinates33°31′S 115°31′E / 33.52°S 115.51°E / -33.52; 115.51Population518 (SAL 2021)[1][2]Established1970sPostcode(s)6271Elevation16 m (52 ft)Area1.6 km2 (0.62 sq mi)Location 8 km (5 mi) NW of Capel 201 km (125 mi) SSW of Perth LGA(s)Shire of CapelState electorat…
Chaos;Headカオスヘッド(Kaosu Heddo)GenreAksi, Psikologis, Romantis, Fiksi ilmiah, Supernatural, Thriller AnimeChaos;HeadSutradaraIshiyama TakaakiStudioMadhouse Portal anime dan manga Chaos;Head (カオスヘッドcode: ja is deprecated , Kaosu Heddo) adalah sebuah game Visual Novel Jepang yang dikembangkan oleh 5pb. dan Nitroplus pada tanggal 25 April 2008 untuk PC. Pada tanggal 26 Februari 2009, dirilis pula untuk versi Xbox 360nya yang berjudul Chaos;Head Noah (カオスヘ…
Gusnul Yakin (lahir 17 Maret 1956) adalah pelatih sepak bola berkewarganegaraan Indonesia. Dia adalah mantan pelatih klub Liga Super 2008/09 Arema Malang dari 13 Agustus 2008 hingga 30 Juni 2009.[1] Gusnul merupakan mantan pemain sepak bola. Sebelumnya Gusnul melatih Persibo Bojonegoro dan berhasil membawa klub tersebut menjadi juara Divisi Satu 2007 yang membuat Persibo berkompetisi di Divisi Utama musim 2008. Karier di Arema Malang Menggantikan Bambang Nurdiansyah saat musim kompetisi …
Emanuel Melkiades Laka Lena Anggota Dewan Perwakilan Rakyat Republik IndonesiaPetahanaMulai menjabat 1 Oktober 2019PresidenJoko WidodoDaerah pemilihanNusa Tenggara Timur II Informasi pribadiLahir10 Desember 1976 (umur 47)Kupang, Nusa Tenggara TimurPartai politikGolkarSuami/istriMindriyati AstiningsihAnak1Alma materUniversitas Sanata DharmaSunting kotak info • L • B Emanuel Melkiades Laka Lena (lahir 10 Desember 1976) adalah politikus Indonesia yang menjabat sebagai anggota…
Garret Augustus HobartGarret Augustus Hobart Wakil Presiden Amerika Serikat 24Masa jabatan4 Maret 1897 – 21 November 1899 PendahuluAdlai E. StevensonPenggantiTheodore Roosevelt Informasi pribadiPartai politikRepublicanSuami/istriJennie Tuttle HobartPekerjaanPengacaraSunting kotak info • L • B Garret Augustus Hobart, ialah Wakil Presiden AS. Dilahirkan dekat Long Branch, New Jersey, pada 3 Juni 1844; mengikuti sekolah umum dan lulus dari Rutgers College, New Brunswick…
Dixit memfilmkan Dance Deewane pada 2018 Madhuri Dixit adalah seorang pemeran India yang dikenal atas karyanya dalam perfilman Bollywood. Ia memulai debutnya dengan berperan sebagai seorang mempelai muda dalam film 1984 Abodh.[1] Dixit tampil dalam beberapa film sepanjang dua tahun berikutnya, meliputi film drama Awara Baap (1985) dan Swati (1986), walaupun tak ada yang meraih sambutan besar.[1] Peran terobosannya datang pada 1988 dengan film cerita seru garapan N. Chandra Tezaab…
This list needs additional citations for verification. Please help improve this article by adding citations to reliable sources in this list. Unsourced material may be challenged and removed.Find sources: List of Christian hip hop artists – news · newspapers · books · scholar · JSTOR (June 2015) (Learn how and when to remove this template message) This is a list of artists who perform within the Christian hip hop subgenre, a subgenre of both hip hop m…
Emoji terong yang tampil di Twitter. 🍆 Emoji terong, juga dikenal dengan nama Unicode Aubergine, adalah sebuah emoji yang menampilkan terong ungu. Emoji tersebut adalah salah satu emoji yang paling banyak dipakai di situs-situs web media sosial seperti Facebook, Twitter, dan Instagram. Para pengguna media sosial menggunakan penampilan phallik dari emoji tersebut dan sering memakainya sebagai ikon eufemistik atau sugestif pada perbincangan sexting.[1] Popularitas di media sosial dan da…
Artikel ini sebatang kara, artinya tidak ada artikel lain yang memiliki pranala balik ke halaman ini.Bantulah menambah pranala ke artikel ini dari artikel yang berhubungan atau coba peralatan pencari pranala.Tag ini diberikan pada Oktober 2022. Mufassar (dalam bahasa Arab berarti dijelaskan) menurut istilah ushul fikih mengarah kepada suatu lafal atau kalimat yang menunjukkan suatu hukum dengan dalalah, yakni petunjuk yang jelas, tanpa menerima kemungkinan penakwilan dan pertakhsisan (pengkhusus…
BawuDesaNegara IndonesiaProvinsiJawa TengahKabupatenJeparaKecamatanBatealitKode pos59461Kode Kemendagri33.20.05.2004 Luas... km²Jumlah penduduk... jiwaKepadatan... jiwa/km² Rumah lurah Bawu pada masa Hindia Belanda Bawu adalah sebuah desa yang berada di kecamatan Batealit, Kota Jepara, Provinsi Jawa Tengah, Negara Indonesia. Geografis Desa Bawu berada disebelah Utara berbatasan dengan desa Bantrung dan desa Kecapi, sedangkan di sebalah selatan berbatasan dengan desa Ngasem dan Ngabul, pad…
Lambang dengan keterangan cupio dissolvi (stucco dan langit-langit bergambar yang berasal dari sekitar tahun 1756, Höchstädt an der Donau). Cupio dissolvi adalah sebuah peribahasa Latin yang dipakai dalam terjemahan Vulgata dari Surat Paulus kepada Jemaat di Filipi. Frase tersebut memiliki arti Aku ingin pergi, menyiratkan keinginan umat Kristen untuk meninggalkan kehidupan duniawi dan bergabung dengan Kristus dalam kehidupan abadi. Ini memainkan peran penting dalam diskusi soal topik bunuh di…
Artikel ini perlu diwikifikasi agar memenuhi standar kualitas Wikipedia. Anda dapat memberikan bantuan berupa penambahan pranala dalam, atau dengan merapikan tata letak dari artikel ini. Untuk keterangan lebih lanjut, klik [tampil] di bagian kanan. Mengganti markah HTML dengan markah wiki bila dimungkinkan. Tambahkan pranala wiki. Bila dirasa perlu, buatlah pautan ke artikel wiki lainnya dengan cara menambahkan [[ dan ]] pada kata yang bersangkutan (lihat WP:LINK untuk keterangan lebih lanjut). …
Comic book series Ultimate Fantastic FourCover to Ultimate Fantastic Four #39Art by Salvador LarrocaPublication informationPublisherMarvel ComicsScheduleMonthlyFormatOngoing seriesGenre Superhero Publication dateFebruary 2004 – February 2009No. of issues60Main character(s)Reed RichardsSusan StormJohnny StormBenjamin GrimmCreative teamCreated byBrian Michael BendisMark MillarAdam Kubert(based upon the original characters by Stan Lee and Jack Kirby)Written byBrian Michael Bendis a…